Categories | Inventors

pLXSN human KIT D816Y retrovirally transduced BaF3 cells


OHSU # 1658-B

Technology Overview:

Technology Overview
Neomycin resistant and growth factor independent. This cell line expresses high levels of activated KIT. In addition to the engineered D816Y mutation, the cells also acquired the following mutations due to retrovirus recombination events: N587S and deletion of amino acids 931-961. These secondary events do not appear to alter the kinase properties of KIT or alter the pattern of D816Y sensitivity/resistance to kinase inhibitors.



For more information, contact:

Trina Voss
Technology Development Manager

(terms)  $0.00
(terms)  $10000.00